Could a Pre-Surgery drug slash recurrence in rare joint tumors?
NCT ID NCT07707882
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial investigates whether taking pimicotinib—a drug that blocks a protein driving tumor growth—for 12 weeks before surgery can improve outcomes for people with diffuse tenosynovial giant cell tumor (D-TGCT), a rare but aggressive joint tumor with a high recurrence rate. Participants are randomly assigned to receive either pimicotinib followed by surgery or surgery alone. The study measures how long patients stay free of events like recurrence or progression, aiming to see if the drug-surgery combo reduces the need for repeat operations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pimicotinib, a CSF1R inhibitor taken orally, followed by tumor removal surgery
- What this could lead to
- If successful, this approach could lower the high recurrence rate of diffuse TGCT and reduce the need for repeat surgeries.
- What could go wrong
- This is a phase 2 trial with only 84 participants, so results may not apply broadly. Pimicotinib can cause side effects like itching, swelling, and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Orthopedics, The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.